Intraductal carcinoma
Methodology & AI Transparency ⓘ
Intraductal carcinoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as C80.1, Intraductal carcinoma falls under Cancer & Oncology management, where tissue biopsy with in Intraductal carcinoma (C80.1: histopathology) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Intraductal carcinoma uses ICD-10 C80.1 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Primary evaluation for Intraductal carcinoma incorporates tissue biopsy with in Intraductal carcinoma (C80.1: histopathology) and symptom diary review.
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Intraductal carcinoma (C80.1): Complete Blood Count in Intraductal carcinoma (C80.1: (ANC, Hemoglobin, Platelets)) & Comprehensive Metabolic & in Intraductal carcinoma (C80.1: Organ Function Panel) (Preserved renal/hepatic clearance (C80.1)).
Ask our AI Specialists anything about Intraductal carcinoma
What Is Intraductal carcinoma?
Designated in federal medical registries as C80.1, Intraductal carcinoma falls under Cancer & Oncology management, where tissue biopsy with in Intraductal carcinoma (C80.1: histopathology) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Intraductal carcinoma (C80.1, Cancer & Oncology) reflects local tissue remodeling [Intraductal carcinoma C80.1]. longitudinal control is benchmarked via Complete Blood Count in Intraductal carcinoma (C80.1: (ANC, Hemoglobin, Platelets)).
Common Symptoms & Clinical Signs
- • Presentation of Intraductal carcinoma (C80.1): unexplained bleeding, chronic in Intraductal carcinoma (C80.1: hoarseness/cough, or progressive)
- • Secondary Intraductal carcinoma clinical sign: abnormality detected early in Intraductal carcinoma (C80.1: on age-appropriate screening)
- • Symptom flares in Intraductal carcinoma correlating with Complete Blood Count in Intraductal carcinoma (C80.1: (ANC, Hemoglobin, Platelets)) deviation outside Safe hematologic reserve (C80.1)
- • Functional cancer & oncology impact requiring tissue biopsy with in Intraductal carcinoma (C80.1: histopathology) evaluation (C80.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Intraductal carcinoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C80.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Intraductal carcinoma (C80.1: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C80.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Intraductal carcinoma (C80.1: Organ Function Panel) | Preserved renal/hepatic clearance (C80.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Intraductal carcinoma (C80.1: Genomic Staging) | Guideline-concordant surveillance (C80.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Intraductal carcinoma
Treatment selection for Intraductal carcinoma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Intraductal carcinoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on PRINCE-BC trial: precision regional irradiation of nodal stations for clinical: What a 1,355-Participant Study Found TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT05976412 (https://clinicaltrials.gov/search?term=NCT05976412). BMC cancer • 2026-04-07 • Phase III Randomized Trial | N = 1,355 | 90/100 | PMID 41947078 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of short-term oral phytoestrogen supplementation on the Phytoestrogen treatment interferes with HPT axis in CaP patients by inducing testicular resistance to LH and compensated hypogonadism. The Prostate • 2006-07-01 • Randomized Controlled Trial | N = 40 | 88/100 | PMID 16637075 ↗ |
| New Insights on Prognostic value of patient-reported outcomes for survival in patients with: What a 283-Participant Study Found Baseline PROs, including dyspnea and physical functioning, have significant prognostic value for survival for patients with advanced non-small cell lung cancer. Frontiers in immunology • 2025-01-15 • Phase III Randomized Trial | N = 283 | 87/100 | PMID 41194933 ↗ |
| New Insights on Atezolizumab with enzalutamide versus enzalutamide alone in metastatic: What a 759-Participant Study Found Together these data indicate that the expected biology associated with response to immune checkpoint inhibitors is present in prostate cancer, albeit in fewer patients. Nature medicine • 2022-01-15 • Phase III Randomized Trial | N = 759 | 87/100 | PMID 35013615 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients GV1001 plus gemcitabine/capecitabine improved OS and TTP compared to gemcitabine/capecitabine alone in eotaxin-high patients with advanced PDAC. British journal of cancer • 2024-01-15 • Phase III Randomized Trial | N = 75 | 82/100 | PMID 37903909 ↗ |
Intraductal carcinoma Patient Community & “People Like Me” Threads
Filter Intraductal carcinoma community threads and patient logs by age, biological sex, dosage, and treatment duration.